Monopar Therapeutics financial data

Symbol
MNPR on Nasdaq
Location
Wilmette, IL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 3.6% % -84%
Return On Equity -26% % 76%
Return On Assets -25% % 72%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6,682,584 shares 27%
Common Stock, Shares, Outstanding 6,662,930 shares 89%
Entity Public Float $6,413,187 USD 39%
Common Stock, Value, Issued $6,663 USD 89%
Weighted Average Number of Shares Outstanding, Basic 7,123,849 shares 102%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $15,887,744 USD 286%
General and Administrative Expense $5,736,087 USD 99%
Operating Income (Loss) $21,623,830 USD -209%
Net Income (Loss) Attributable to Parent $19,441,707 USD -200%
Earnings Per Share, Basic -3 USD/shares -17%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $127,677,360 USD 2021%
Other Assets, Current $414,825 USD 737%
Assets, Current $144,090,612 USD 2274%
Operating Lease, Right-of-Use Asset $106,666 USD
Assets $144,197,278 USD 2276%
Liabilities, Current $2,568,549 USD
Operating Lease, Liability, Noncurrent $70,881 USD
Liabilities $2,639,430 USD 135%
Accumulated Other Comprehensive Income (Loss), Net of Tax $11,698 USD
Retained Earnings (Accumulated Deficit) $84,308,735 USD -30%
Stockholders' Equity Attributable to Parent $141,557,848 USD 2762%
Liabilities and Equity $144,197,278 USD 2276%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,663,316 USD -242%
Net Cash Provided by (Used in) Financing Activities $115,682 USD -104%
Net Cash Provided by (Used in) Investing Activities $325,828 USD 67%
Common Stock, Shares Authorized 40,000,000 shares 0%
Common Stock, Shares, Issued 6,662,930 shares 89%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $6,104,880 USD -1227%
Deferred Tax Assets, Valuation Allowance $17,871,635 USD 35%
Deferred Tax Assets, Gross $17,871,635 USD 35%
Operating Lease, Liability $102,236 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $19,359,657 USD -198%
Lessee, Operating Lease, Liability, to be Paid $110,800 USD
Operating Lease, Liability, Current $31,355 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $42,960 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $43,810 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $8,564 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $10,740 USD
Deferred Tax Assets, Operating Loss Carryforwards $4,476,675 USD 16%
Unrecognized Tax Benefits $411,740 USD 23%
Deferred Tax Assets, Net of Valuation Allowance $0 USD